{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:40:24Z","timestamp":1756464024429},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,23]],"date-time":"2009-09-23T00:00:00Z","timestamp":1253664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s00280-009-1145-z","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T09:02:51Z","timestamp":1253610171000},"page":"151-158","source":"Crossref","is-referenced-by-count":10,"title":["A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors"],"prefix":"10.1007","volume":"66","author":[{"given":"Bhuvaneswari","family":"Ramaswamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory B.","family":"Lesinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donn C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy","family":"Culler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diedre","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,23]]},"reference":[{"issue":"Suppl 1","key":"1145_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","volume":"29","author":"J Adams","year":"2003","unstructured":"Adams J (2003) The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29(Suppl 1):3\u20139","journal-title":"Cancer Treat Rev"},{"key":"1145_CR2","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1073\/pnas.95.6.2727","volume":"95","author":"A Ciechanover","year":"1998","unstructured":"Ciechanover A, Schwartz AL (1998) The ubiquitin\u2013proteasome pathway: the complexity and myriad functions of proteins death [comment]. Proc Natl Acad Sci USA 95:2727\u20132730","journal-title":"Proc Natl Acad Sci USA"},{"key":"1145_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","volume":"7","author":"J Adams","year":"2002","unstructured":"Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7:9\u201316","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"1145_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0305-7372(03)00079-3","volume":"29","author":"JC Cusack","year":"2003","unstructured":"Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21\u201331","journal-title":"Cancer Treat Rev"},{"key":"1145_CR5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2404444","volume":"21","author":"A Nencioni","year":"2007","unstructured":"Nencioni A, Grunebach F, Patrone F et al (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia 21:30\u201336","journal-title":"Leukemia"},{"key":"1145_CR6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","volume":"78","author":"VJ Palombella","year":"1994","unstructured":"Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin\u2013proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773\u2013785","journal-title":"Cell"},{"key":"1145_CR7","first-page":"841","volume":"1","author":"YH Ling","year":"2002","unstructured":"Ling YH, Liebes L, Ng B et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841\u2013849","journal-title":"Mol Cancer Ther"},{"key":"1145_CR8","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment]. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"},{"key":"1145_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165\u2013172","journal-title":"Br J Haematol"},{"key":"1145_CR10","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma [see comment]. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"1145_CR11","unstructured":"Millennium Pharmaceuticals I. Velcade Full Prescribing Information. June 2008"},{"key":"1145_CR12","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","volume":"22","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108\u20132121","journal-title":"J Clin Oncol"},{"key":"1145_CR13","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649\u20131657","journal-title":"Clin Cancer Res"},{"key":"1145_CR14","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ejca.2007.01.038","volume":"43","author":"A Milano","year":"2007","unstructured":"Milano A, Iaffaioli RV, Caponigro F (2007) The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 43:1125\u20131133","journal-title":"Eur J Cancer"},{"key":"1145_CR15","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1210\/jc.2005-2472","volume":"91","author":"CS Mitsiades","year":"2006","unstructured":"Mitsiades CS, McMillin D, Kotoula V et al (2006) Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91:4013\u20134021","journal-title":"J Clin Endocrinol Metab"},{"key":"1145_CR16","first-page":"4342","volume":"58","author":"RZ Orlowski","year":"1998","unstructured":"Orlowski RZ, Eswara JR, Lafond-Walker A et al (1998) Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res 58:4342\u20134348","journal-title":"Cancer Res"},{"key":"1145_CR17","first-page":"2638","volume":"5","author":"BA Teicher","year":"1999","unstructured":"Teicher BA, Ara G, Herbst R et al (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638\u20132645","journal-title":"Clin Cancer Res"},{"key":"1145_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/sj.cdd.4400505","volume":"6","author":"RZ Orlowski","year":"1999","unstructured":"Orlowski RZ (1999) The role of the ubiquitin\u2013proteasome pathway in apoptosis. Cell Death Differ 6:303\u2013313","journal-title":"Cell Death Differ"},{"key":"1145_CR19","doi-asserted-by":"crossref","unstructured":"Cresta SSC, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Vigano L, maur M, Capri G, Maccioni E, Tosi D, Gianni L (2008) Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumors. Eur J Cancer. doi: 10.1016\/j.ejca.2008.05.022","DOI":"10.1016\/j.ejca.2008.05.022"},{"key":"1145_CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-006-0259-9","volume":"59","author":"C Ma","year":"2007","unstructured":"Ma C, Mandrekar SJ, Alberts SR et al (2007) A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59:207\u2013215","journal-title":"Cancer Chemother Pharmacol"},{"key":"1145_CR21","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-05-0437","volume":"5","author":"SE Canfield","year":"2006","unstructured":"Canfield SE, Zhu K, Williams SA, McConkey DJ (2006) Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 5:2043\u20132050","journal-title":"Mol Cancer Ther"},{"key":"1145_CR22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/00001622-200211000-00007","volume":"14","author":"J Adams","year":"2002","unstructured":"Adams J (2002) Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14:628\u2013634","journal-title":"Curr Opin Oncol"},{"key":"1145_CR23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jnci\/92.3.179","volume":"92","author":"EA Gehan","year":"2000","unstructured":"Gehan EA, Tefft MC (2000) Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? [comment]. J Natl Cancer Inst 92:179\u2013181","journal-title":"J Natl Cancer Inst"},{"key":"1145_CR24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","volume":"46","author":"ES Lightcap","year":"2000","unstructured":"Lightcap ES, McCormack TA, Pien CS et al (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673\u2013683","journal-title":"Clin Chem"},{"key":"1145_CR25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2002-12-3794","volume":"102","author":"JL Aron","year":"2003","unstructured":"Aron JL, Parthun MR, Marcucci G et al (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102:652\u2013658","journal-title":"Blood"},{"key":"1145_CR26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/annonc\/mdj131","volume":"17","author":"CH Yang","year":"2006","unstructured":"Yang CH, Gonzalez-Angulo AM, Reuben JM et al (2006) Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17:813\u2013817","journal-title":"Ann Oncol"},{"key":"1145_CR27","first-page":"2505","volume":"8","author":"C Aghajanian","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505\u20132511","journal-title":"Clin Cancer Res"},{"key":"1145_CR28","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/sj.bjc.6604347","volume":"98","author":"A Awada","year":"2008","unstructured":"Awada A, Albanell J, Canney PA et al (2008) Bortezomib\/docetaxel combination therapy in patients with anthracycline-pretreated advanced\/metastatic breast cancer: a phase I\/II dose-escalation study. Br J Cancer 98:1500\u20131507","journal-title":"Br J Cancer"},{"key":"1145_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COC.0b013e31805c142f","volume":"31","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Engstrom PF, Lewis NL et al (2008) Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Am J Clin Oncol 31:1\u20135","journal-title":"Am J Clin Oncol"},{"key":"1145_CR30","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-06-2046","volume":"13","author":"R Dreicer","year":"2007","unstructured":"Dreicer R, Petrylak D, Agus D et al (2007) Phase I\/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13:1208\u20131215","journal-title":"Clin Cancer Res"},{"key":"1145_CR31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archderm.1963.01590230105015","volume":"88","author":"H Pinkus","year":"1963","unstructured":"Pinkus H, Mehregan AH (1963) Epidermotropic eccrine carcinoma: a case combining features of eccrine poroma and Paget\u2019s dermatosis. Arch Dermatol 88:597\u2013606","journal-title":"Arch Dermatol"},{"key":"1145_CR32","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/1097-0142(19921015)70:8<2099::AID-CNCR2820700815>3.0.CO;2-C","volume":"70","author":"SN Snow","year":"1992","unstructured":"Snow SN, Reizner GT (1992) Mucinous eccrine carcinoma of the eyelid. Cancer 70:2099\u20132104","journal-title":"Cancer"},{"key":"1145_CR33","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00000478-200106000-00002","volume":"25","author":"A Robson","year":"2001","unstructured":"Robson A, Greene J, Ansari N (2001) Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases [see comment]. Am J Surg Pathol 25:710\u2013720","journal-title":"Am J Surg Pathol"},{"key":"1145_CR34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1468-3083.2004.00949.x","volume":"18","author":"J Gutermuth","year":"2004","unstructured":"Gutermuth J, Audring H, Voit C et al (2004) Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Venereol 18:477\u2013479","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1145_CR35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MPA.0b013e31815b3207","volume":"36","author":"B Holcomb","year":"2008","unstructured":"Holcomb B, Yip-Schneider M, Schmidt CM (2008) The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 36:225\u2013235","journal-title":"Pancreas"},{"key":"1145_CR36","doi-asserted-by":"crossref","unstructured":"Ashamalla H, Zaki B, Mokhtar B et al. (2003) Hyperfractionated radiotherapy and paclitaxel for locally advanced\/unresectable pancreatic cancer [erratum appears in Int J Radiat Oncol Biol Phys. Mar 15; 55(4):1158]. Int J Radiat Oncol Biol Phys 55: 679\u2013687","DOI":"10.1016\/S0360-3016(02)03791-4"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1145-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1145-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1145-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T10:51:45Z","timestamp":1590144705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1145-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,23]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1145-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,23]]}}}